Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen?

被引：24
|
作者：
Einhorn, LH [1 ]
Foster, RS
机构：
[1] Indiana Univ, Dept Med, Indianapolis, IN 46204 USA
[2] Indiana Univ, Dept Urol, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 16期
关键词：
D O I：
10.1200/JCO.2006.05.6184
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2597 / 2598
页数：2
相关论文
共 50 条
  • [41] One cycle of bleomycin, etoposide and cisplatin plus two cycles of etopeside and cisplatin chemotherapy in selected patients with low-volume stage II nonseminomatous germ cell tumor of the testis
    Mezvrishvili, Z
    Managadze, L
    UROLOGIA INTERNATIONALIS, 2005, 75 (04) : 304 - 308
  • [42] HIGH-RISK GERM-CELL TUMORS IN MEN - HIGH RESPONSE RATE AND SEVERE TOXICITY WITH CISPLATIN, VINBLASTINE, BLEOMYCIN, AND ETOPOSIDE
    BLAYNEY, DW
    GOLDBERG, DA
    LEONG, LA
    MARGOLIN, KA
    BURKE, JS
    DOROSHOW, JH
    CANCER, 1993, 71 (07) : 2351 - 2357
  • [43] Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients - A single-center study
    Tscherry, G
    Jacky, E
    Jost, LM
    Stahel, RA
    ONCOLOGY, 2000, 59 (02) : 110 - 117
  • [44] TREATMENT OF FAVORABLE-PROGNOSIS NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS WITH ETOPOSIDE, CISPLATIN, AND REDUCED DOSE OF BLEOMYCIN
    BRADA, M
    HORWICH, A
    PECKHAM, MJ
    CANCER TREATMENT REPORTS, 1987, 71 (06): : 655 - 656
  • [45] ADJUVANT THERAPY OF OVARIAN GERM-CELL TUMORS WITH CISPLATIN, ETOPOSIDE, AND BLEOMYCIN - A TRIAL OF THE GYNECOLOGIC-ONCOLOGY-GROUP
    WILLIAMS, S
    BLESSING, JA
    LIAO, SY
    BALL, H
    HANJANI, P
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 701 - 706
  • [46] ETOPOSIDE AND HIGH-DOSE CISPLATIN IN GOOD-RISK PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE LUNG
    ARDIZZONI, A
    CANOBBIO, L
    PRONZATO, P
    RUBAGOTTI, A
    DEPALMA, M
    BARACCO, F
    SERRANO, J
    SERRANO, S
    FARAVELLI, B
    NOSENZO, M
    FELLETTI, R
    ROSSO, R
    CANCER TREATMENT REPORTS, 1986, 70 (07): : 891 - 892
  • [47] Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council European Organization for Research and Treatment of Cancer Trial
    Horwich, A
    Sleijfer, DT
    Fossa, SD
    Kaye, SB
    Oliver, RTD
    Cullen, MH
    Mead, GM
    deWit, R
    deMulder, PHM
    Dearnaley, DP
    Cook, PA
    Sylvester, RJ
    Stenning, SP
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1844 - 1852
  • [48] ETOPOSIDE, CISPLATIN, BLEOMYCIN, AND CYCLOPHOSPHAMIDE (ECBC) AS 1ST-LINE CHEMOTHERAPY FOR POOR-RISK NONSEMINOMATOUS GERM-CELL TUMORS
    GERL, A
    CLEMM, C
    HENTRICH, M
    HARTENSTEIN, R
    WILMANNS, W
    ACTA ONCOLOGICA, 1993, 32 (05) : 541 - 546
  • [49] Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
    Cafferty, Fay H.
    White, Jeff D.
    Shamash, Jonathan
    Hennig, Ivo
    Stenning, Sally P.
    Huddart, Robert A.
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 139 - 149
  • [50] A PHASE-II STUDY OF HIGH-DOSE CISPLATIN, VINBLASTINE, BLEOMYCIN, AND ETOPOSIDE (PVEBV REGIMEN) IN MALIGNANT NONDYSGERMINOMATOUS GERM-CELL TUMORS OF THE OVARY
    CULINE, S
    KATTAN, J
    LHOMME, C
    DUVILLARD, P
    MICHEL, G
    CASTAIGNE, D
    LECLERE, J
    PICO, J
    DROZ, JP
    GYNECOLOGIC ONCOLOGY, 1994, 54 (01) : 47 - 53
12345